Management guidelines for preventing exposure to antineoplastics

Chin J Cancer Res. 2023 Feb 28;35(1):1-10. doi: 10.21147/j.issn.1000-9604.2023.01.01.

Authors

Wei Liu^{1

2}, Ziyang Wu^{1

2}, Tong Sun¹, Shuyao Liang¹, Jun Zhu³, Suodi Zhai^{1

2}, Division Of Therapeutic Drug Monitoring Of Chinese Pharmacological Society^{1

2

3}, Hospital Pharmacy Professional Committee Of Chinese Pharmaceutical Association^{1

2

3}, Oncology Society Of Chinese Medical Association^{1

2

3}, Nursing Branch Of China International Exchange And Promotive Association For Medical And Healthcare^{1

2

3}, Division Of Drug-Induced Diseases Of Chinese Pharmacology Society^{1

2

3}

Affiliations

¹ Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
² Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China.
³ Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.

PMID: 36910857
PMCID: PMC9992999
DOI: 10.21147/j.issn.1000-9604.2023.01.01

No abstract available